PFE
Pfizer Inc. NYSE Listed Jun 1, 1972$26.48
Mkt Cap $150.6B
52w Low $21.97
66.4% of range
52w High $28.75
50d MA $27.10
200d MA $25.72
P/E (TTM)
19.4x
EV/EBITDA
13.8x
P/B
1.7x
Debt/Equity
0.8x
ROE
9.0%
P/FCF
15.6x
RSI (14)
—
ATR (14)
—
Beta
0.39
50d MA
$27.10
200d MA
$25.72
Avg Volume
41.1M
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
66 Hudson Boulevard East · New York City, NY 10001-2192 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | TNS | 0.72 | 0.75 | +3.9% | 26.45 | +0.4% | +0.3% | +0.1% | — | — | — | — |
| Feb 3, 2026 | TNS | 0.57 | 0.66 | +16.4% | 25.77 | +0.4% | +3.9% | +3.9% | +2.8% | +5.6% | +5.0% | — |
| Nov 4, 2025 | TNS | 0.63 | 0.87 | +37.4% | 24.30 | +0.3% | +1.3% | +1.3% | +2.3% | +0.5% | +0.4% | — |
| Aug 5, 2025 | TNS | 0.58 | 0.78 | +34.5% | 24.75 | -0.3% | -3.3% | -3.3% | -2.1% | -0.7% | -0.7% | — |
| Apr 29, 2025 | TNS | 0.67 | 0.92 | +38.1% | 23.79 | +1.7% | +2.6% | +2.6% | +0.6% | +1.7% | +0.3% | — |
| Feb 4, 2025 | TNS | 0.47 | 0.63 | +33.6% | 25.87 | +0.3% | +2.2% | +2.2% | -0.2% | -0.5% | +0.0% | — |
| Oct 29, 2024 | TNS | 0.61 | 1.06 | +72.6% | 28.46 | -0.5% | +0.2% | +0.2% | -0.6% | -1.3% | -2.5% | — |
| Jul 30, 2024 | TNS | 0.46 | 0.60 | +31.0% | 31.39 | -0.6% | -2.7% | -2.7% | -2.4% | -3.1% | -5.3% | — |
| May 1, 2024 | TNS | 0.52 | 0.82 | +58.9% | 27.18 | +0.1% | +1.9% | +1.9% | +2.3% | +3.6% | +2.2% | — |
| Jan 30, 2024 | TNS | -0.19 | 0.10 | +152.6% | 27.02 | +0.6% | +0.2% | +0.2% | +1.0% | -0.3% | -1.7% | — |
| Oct 31, 2023 | TNS | -0.32 | -0.17 | +46.9% | 30.56 | +0.0% | -0.2% | -0.2% | -0.2% | +2.3% | +2.0% | — |
| Aug 1, 2023 | TNS | 0.56 | 0.67 | +19.6% | 35.61 | +0.1% | -0.7% | -0.7% | -1.7% | -1.7% | +0.2% | — |
| May 2, 2023 | BMO | 0.98 | 1.23 | +25.5% | 39.06 | +0.4% | -1.6% | -1.6% | -2.1% | -1.5% | -1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | RBC Capital | Maintains | Underperform → Underperform | — | $27.56 | $27.59 | +0.1% | -0.1% | -0.9% | -2.8% | -3.2% | -2.0% |
| Apr 13 | UBS | Maintains | Neutral → Neutral | — | $26.92 | $26.83 | -0.3% | +1.6% | +0.7% | +1.0% | +1.1% | +2.4% |
| Apr 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $27.22 | $27.32 | +0.4% | -1.1% | +0.4% | -0.4% | -0.1% | +0.0% |
| Apr 9 | BofA Securities | Maintains | Neutral → Neutral | — | $27.47 | $27.21 | -0.9% | -0.9% | -2.0% | -0.5% | -1.3% | -1.0% |
| Mar 24 | Guggenheim | Maintains | Buy → Buy | — | $26.77 | $26.60 | -0.6% | +0.7% | +1.9% | +3.0% | +1.0% | +3.7% |
| Mar 17 | HSBC | Maintains | Buy → Buy | — | $26.61 | $26.82 | +0.8% | +3.2% | +2.7% | +3.0% | +1.4% | +0.6% |
| Mar 2 | Argus | Upgrade | Hold → Buy | — | $27.65 | $27.57 | -0.3% | -1.4% | -3.9% | -3.7% | -3.8% | -2.2% |
| Feb 9 | Freedom Broker | Maintains | Buy → Buy | — | $27.22 | $27.18 | -0.1% | -0.6% | +1.4% | +1.9% | +0.9% | +1.3% |
| Feb 4 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $25.77 | $25.88 | +0.4% | +3.9% | +2.8% | +5.6% | +5.0% | +7.1% |
| Jan 27 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $25.88 | $25.94 | +0.2% | +2.4% | -0.1% | +0.9% | +2.2% | +3.0% |
| Dec 17 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $25.53 | $25.40 | -0.5% | -1.9% | -1.9% | -1.3% | -1.3% | -2.5% |
| Dec 15 | BofA Securities | Maintains | Neutral → Neutral | — | $25.85 | $25.82 | -0.1% | +2.2% | -1.2% | -3.1% | -3.1% | -2.6% |
| Dec 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $25.80 | $25.84 | +0.2% | +0.2% | +2.4% | -1.0% | -2.9% | -2.9% |
| Nov 24 | Guggenheim | Maintains | Buy → Buy | — | $25.04 | $25.11 | +0.3% | +0.7% | +2.7% | +2.7% | +2.8% | +0.9% |
| Oct 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $25.24 | $25.26 | +0.1% | -1.8% | -2.0% | -2.9% | -3.4% | -4.0% |
| Oct 3 | BofA Securities | Maintains | Neutral → Neutral | — | $27.08 | $27.20 | +0.4% | +1.1% | -2.4% | -3.0% | -5.2% | -6.8% |
| Aug 6 | Citigroup | Maintains | Neutral → Neutral | — | $24.75 | $24.68 | -0.3% | -3.3% | -2.1% | -0.7% | -0.7% | -0.4% |
| Aug 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $24.75 | $24.68 | -0.3% | -3.3% | -2.1% | -0.7% | -0.7% | -0.4% |
| Aug 6 | BofA Securities | Maintains | Neutral → Neutral | — | $24.75 | $24.68 | -0.3% | -3.3% | -2.1% | -0.7% | -0.7% | -0.4% |
| Apr 30 | UBS | Maintains | Neutral → Neutral | — | $23.79 | $24.20 | +1.7% | +2.6% | +0.6% | +1.7% | +0.3% | -3.8% |
| Apr 8 | Goldman Sachs | Downgrade | Buy → Neutral | — | $22.63 | $22.90 | +1.2% | -3.5% | -0.6% | -4.6% | -3.2% | -2.3% |
| Apr 8 | UBS | Maintains | Neutral → Neutral | — | $22.63 | $22.90 | +1.2% | -3.5% | -0.6% | -4.6% | -3.2% | -2.3% |
| Mar 18 | Guggenheim | Maintains | Buy → Buy | — | $26.05 | $26.21 | +0.6% | +1.0% | +0.6% | +0.5% | +0.9% | +0.3% |
| Mar 12 | Guggenheim | Maintains | Buy → Buy | — | $25.99 | $25.94 | -0.2% | -1.1% | -1.5% | -1.0% | +0.2% | +1.2% |
| Feb 10 | Guggenheim | Maintains | Buy → Buy | — | $25.74 | $25.78 | +0.2% | +0.5% | -0.8% | -1.0% | -0.4% | -0.8% |
| Feb 5 | UBS | Maintains | Neutral → Neutral | — | $25.87 | $25.95 | +0.3% | +2.2% | -0.2% | -0.5% | +0.0% | -1.3% |
| Jan 28 | Citigroup | Maintains | Neutral → Neutral | — | $26.86 | $26.78 | -0.3% | -0.4% | -0.9% | +0.2% | -1.3% | -2.5% |
| Jan 8 | UBS | Maintains | Neutral → Neutral | — | $27.13 | $27.05 | -0.3% | -1.0% | -1.5% | -1.2% | -2.7% | -3.4% |
| Dec 18 | Truist | Maintains | Buy → Buy | — | $26.43 | $26.19 | -0.9% | -2.0% | -2.5% | -0.3% | +1.1% | +1.2% |
| Dec 11 | Guggenheim | Maintains | Buy → Buy | — | $25.57 | $25.38 | -0.7% | -1.3% | -0.8% | +0.0% | -1.3% | +3.4% |
| Oct 30 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $28.46 | $28.31 | -0.5% | +0.2% | -0.6% | -1.3% | -2.5% | -1.7% |
| Oct 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $28.64 | $28.68 | +0.1% | -0.7% | +0.8% | -0.6% | -0.4% | -1.2% |
| Oct 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $28.84 | $28.87 | +0.1% | +0.1% | -0.7% | -1.4% | +0.1% | -1.3% |
| Oct 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $29.34 | $29.36 | +0.1% | -0.6% | -0.9% | +0.3% | +1.1% | -0.2% |
| Oct 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $28.61 | $28.50 | -0.4% | -0.9% | -0.1% | +2.1% | +2.0% | +5.5% |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $29.27 | $29.57 | +1.0% | +2.7% | +1.9% | +1.6% | +1.3% | +0.5% |
| Sep 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $28.56 | $28.54 | -0.1% | +3.0% | +4.1% | +3.9% | +2.1% | +2.5% |
| Aug 19 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $28.30 | $28.35 | +0.2% | +1.8% | +2.1% | +2.6% | +1.7% | +2.1% |
| Aug 8 | Daiwa Capital | Upgrade | Neutral → Outperform | — | $28.85 | $28.93 | +0.3% | -0.3% | -1.0% | -1.4% | +0.0% | +0.1% |
| Jul 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $31.39 | $31.20 | -0.6% | -2.7% | -2.4% | -3.1% | -5.3% | -6.6% |
| Jul 31 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.39 | $31.20 | -0.6% | -2.7% | -2.4% | -3.1% | -5.3% | -6.6% |
| Jul 31 | UBS | Maintains | Neutral → Neutral | — | $31.39 | $31.20 | -0.6% | -2.7% | -2.4% | -3.1% | -5.3% | -6.6% |
| Jul 31 | Barclays | Maintains | Equal Weight → Equal Weight | — | $31.39 | $31.20 | -0.6% | -2.7% | -2.4% | -3.1% | -5.3% | -6.6% |
| Jul 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $27.72 | $27.83 | +0.4% | +2.3% | +3.4% | +4.3% | +5.0% | +6.4% |
| Jul 10 | Barclays | Maintains | Equal Weight → Equal Weight | — | $27.72 | $27.83 | +0.4% | +2.3% | +3.4% | +4.3% | +5.0% | +6.4% |
| Jul 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $27.98 | $27.95 | -0.1% | +0.9% | -0.5% | -1.0% | +0.3% | -0.2% |
| Jun 26 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $27.99 | $27.91 | -0.3% | -2.0% | -0.7% | -0.0% | +0.8% | -0.6% |
| Jun 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $27.41 | $27.20 | -0.8% | +1.2% | +1.2% | +3.5% | +2.1% | +0.0% |
| Jun 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $27.53 | $27.45 | -0.3% | -2.0% | -0.4% | +0.8% | +0.8% | +3.0% |
| May 2 | BMO Capital | Maintains | Outperform → Outperform | — | $27.18 | $27.21 | +0.1% | +1.9% | +2.3% | +3.6% | +2.2% | +4.0% |
No insider trades available.
8-K · 2.02
!! High
Pfizer Inc. -- 8-K 2.02: Earnings Results
Pfizer reported first-quarter 2026 earnings on May 5, 2026, with results now available for investor review to assess the pharmaceutical giant's operational performance and guidance outlook.
May 5
8-K
Pfizer Inc. -- 8-K Filing
Apr 27
8-K
Pfizer Inc. -- 8-K Filing
Pfizer reaffirmed its 2026 financial guidance, indicating management confidence in its forward outlook despite reporting Q4 and full-year 2025 results.
Feb 3
Data updated apr 26, 2026 7:21pm
· Source: massive.com